LONDON--Research-based pharmaceutical and healthcare company GlaxoSmithKline PLC (GSKl.LN) said Monday that the initial tender offer for Human Genome Sciences Inc (HGSI) expired 0400 GMT on July 26, and at that time 158.61 million shares, or 79%, had been validly tendered and not withdrawn.

MAIN FACTS:

-An additional 9.16 million Human Genome shares, or 4%, were tendered subject to guaranteed delivery procedures.

-GlaxoSmithKline shares at 1235 GMT up 17 pence, or 1.14%, at 1460 pence valuing the company at 72.03 billion pounds.

-Write to Ian Walker at ian.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Human Genome Sciences (NASDAQ:HGSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Human Genome Sciences
Human Genome Sciences (NASDAQ:HGSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Human Genome Sciences